Book contents
- Treatment of Dystonia
- Treatment of Dystonia
- Copyright page
- Contents
- Contributors
- Preface
- 1 Development of the Concept of Dystonia as a Disease, a Syndrome and a Movement Phenomenology
- Section I Basics
- Section II Botulinum Toxin Therapy
- 21 The Global Market for Botulinum Toxin
- 22 Molecular Mechanisms of Botulinum Toxin
- 23 Indirect Central Nervous System Effects of Botulinum Toxin
- 24 Direct Central Nervous System Effects of Botulinum Neurotoxin
- 25 Analgesic Effects of Botulinum Toxins
- 26 Manufacture of Commercial Botulinum Neurotoxins for Human Treatment
- 27 Pharmacology of Botulinum Toxins
- 28 Immunology of Botulinum Toxin Therapy
- 29 Use of Non-A/Non-B Botulinum Toxins
- 30 Clinical Muscular Anatomy for the Botulinum Toxin Injector
- 31 Ultrasound Guidance for Botulinum Toxin Application
- 32 Treatment Algorithms and Injection Schemes for Botulinum Toxin Therapy of Dystonia
- 33 Botulinum Toxin Therapy for Cervical Dystonia
- 34 Botulinum Toxin Therapy for Cranial Dystonia
- 35 Botulinum Toxin Therapy for Spasmodic Dysphonia
- 36 Botulinum Toxin Therapy for Writer’s Cramp and Other Focal Hand Dystonias
- 37 Botulinum Toxin Therapy for Bruxism
- 38 Treatment of Blepharospasm With Eyelid-Opening Apraxia
- 39 Organisation of a Botulinum Toxin Clinic
- Section III Musician’s Dystonia
- Section IV Psychogenic Dystonia
- Section V Treatment of Paediatric Dystonia
- Section VI Rehabilitation of Dystonia
- Section VII Pharmacotherapy for Dystonia
- Section VIII Surgical Treatment of Dystonia
- Section IX Deep Brain Stimulation for Dystonia
- Section X Emerging Therapies for Dystonia
- Section XI Future Trends in Dystonia Therapy
- Book part
- Index
- References
28 - Immunology of Botulinum Toxin Therapy
from Section II - Botulinum Toxin Therapy
Published online by Cambridge University Press: 31 May 2018
Book contents
- Treatment of Dystonia
- Treatment of Dystonia
- Copyright page
- Contents
- Contributors
- Preface
- 1 Development of the Concept of Dystonia as a Disease, a Syndrome and a Movement Phenomenology
- Section I Basics
- Section II Botulinum Toxin Therapy
- 21 The Global Market for Botulinum Toxin
- 22 Molecular Mechanisms of Botulinum Toxin
- 23 Indirect Central Nervous System Effects of Botulinum Toxin
- 24 Direct Central Nervous System Effects of Botulinum Neurotoxin
- 25 Analgesic Effects of Botulinum Toxins
- 26 Manufacture of Commercial Botulinum Neurotoxins for Human Treatment
- 27 Pharmacology of Botulinum Toxins
- 28 Immunology of Botulinum Toxin Therapy
- 29 Use of Non-A/Non-B Botulinum Toxins
- 30 Clinical Muscular Anatomy for the Botulinum Toxin Injector
- 31 Ultrasound Guidance for Botulinum Toxin Application
- 32 Treatment Algorithms and Injection Schemes for Botulinum Toxin Therapy of Dystonia
- 33 Botulinum Toxin Therapy for Cervical Dystonia
- 34 Botulinum Toxin Therapy for Cranial Dystonia
- 35 Botulinum Toxin Therapy for Spasmodic Dysphonia
- 36 Botulinum Toxin Therapy for Writer’s Cramp and Other Focal Hand Dystonias
- 37 Botulinum Toxin Therapy for Bruxism
- 38 Treatment of Blepharospasm With Eyelid-Opening Apraxia
- 39 Organisation of a Botulinum Toxin Clinic
- Section III Musician’s Dystonia
- Section IV Psychogenic Dystonia
- Section V Treatment of Paediatric Dystonia
- Section VI Rehabilitation of Dystonia
- Section VII Pharmacotherapy for Dystonia
- Section VIII Surgical Treatment of Dystonia
- Section IX Deep Brain Stimulation for Dystonia
- Section X Emerging Therapies for Dystonia
- Section XI Future Trends in Dystonia Therapy
- Book part
- Index
- References
Summary
A summary is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
- Type
- Chapter
- Information
- Treatment of Dystonia , pp. 133 - 136Publisher: Cambridge University PressPrint publication year: 2018
References
Biglan, AW, Gonnering, R, Lockhart, LB, Rabin, B, Fuerste, FH (1986) Absence of antibody production in patients treated with botulinum A toxin. Am J Ophthalmol 101:232–235.CrossRefGoogle ScholarPubMed
Birklein, F, Walther, D, Bigalke, H, Winterholler, M, Erbguth, F (2002) Sudomotor testing predicts the presence of neutralizing botulinum A toxin antibodies. Ann Neurol 52:68–73.CrossRefGoogle ScholarPubMed
Dressler, D (2000b) Complete secondary botulinum toxin therapy failure in blepharospasm. J Neurol 247:809–810.CrossRefGoogle ScholarPubMed
Dressler, D (2004a) New formulation of BOTOX®: complete antibody-induced therapy failure in hemifacial spasm. J Neurol 251:360.Google Scholar
Dressler, D (2004b) Clinical presentation and management of antibody-induced failure of botulinum toxin therapy. Mov Disord 19 (Suppl. 8):S92–S100.Google Scholar
Dressler, D (2012) Five-year experience with incobotulinumtoxinA (Xeomin®): the first botulinum toxin drug free of complexing proteins. Eur J Neurol 19:385–389.CrossRefGoogle ScholarPubMed
Dressler, D, Adib Saberi, F (2016) Immunological safety of incobotulinumtoxinA (Xeomin®) therapy with reduced interinjection intervals. J Neural Transm 122:327–333.CrossRefGoogle Scholar
Dressler, D, Bigalke, H (2002) Botulinum toxin antibody titres after cessation of botulinum toxin therapy. Mov Disord 17:170–173.CrossRefGoogle ScholarPubMed
Dressler, D, Dirnberger, G (2000) Botulinum toxin therapy: risk factors for therapy failure. Mov Disord 15 (Suppl. 2):51.Google Scholar
Dressler, D, Foster, K (in press) Pharmacology of botulinum toxins. In: Dressler, D, Altenmüller, E, Krauss, JK (eds) Treatment of Dystonia. Cambridge: Cambridge University Press.Google Scholar
Dressler, D, Zettl, U, Bigalke, H, Benecke, R (2000a) Can intravenous immunoglobulin improve antibody mediated botulinum toxin therapy failure? Mov Disord 15:1279–1281.3.0.CO;2-4>CrossRefGoogle ScholarPubMed
Dressler, D, Dirnberger, G, Bhatia, K, Quinn, NP, Irmer, A, Bigalke, H, Marsden, CD (2000b) Botulinum toxin antibody testing: comparison between the mouse diaphragm bioassay and the mouse lethality bioassay. Mov Disord 15:973–976.3.0.CO;2-X>CrossRefGoogle Scholar
Dressler, D, Bigalke, H, Rothwell, JC (2000c) The sternocleidomastoid test: an in-vivo assay to investigate botulinum toxin antibody formation in man. J Neurol 247:630–632.Google Scholar
Dressler, D, Muenchau, A, Bhatia, KP, Quinn, NP, Bigalke, H (2002) Antibody induced botulinum toxin therapy failure: can it be overcome by increased botulinum toxin doses? Eur Neurol 47:118–121.CrossRefGoogle ScholarPubMed
Dressler, D, Benecke, R, Bigalke, H (2003) Botulinum toxin type B (NeuroBloc®) in patients with botulinum toxin type A antibody-induced therapy failure. J Neurol 250:967–969.CrossRefGoogle Scholar
Dressler, D, Wohlfahrt, K, Meyer-Rogge, E, Wiest, L, Bigalke, H (2010) Antibody-induced failure of botulinum toxin a therapy in cosmetic indications. Dermatol Surg 36 (Suppl. 4):2182–2187.Google Scholar
Dressler, D, Adib Saberi, F, Kollewe, K, Schrader, C (2014a) Safety aspects of incobotulinumtoxinA high dose therapy. J Neural Transm 122:327–333.Google Scholar
Dressler, D, Gessler, F, Tacik, P, Bigalke, H (2014b) An enzyme-linked immunosorbent assay for detection of botulinum toxin-antibodies. Mov Disord 29:1322–1324.Google Scholar
Dressler, D, Altenmueller, E, Bhidayasiri, R, Bohlega, S, Chana, P, Chung, TM, Frucht, S, Garcia-Ruiz, PJ, Kaelin, A, Kaji, R, Kanovsky, P, Laskawi, R, Micheli, F, Orlova, O, Relja, M, Rosales, R, Slawek, J, Timerbaeva, S, Warner, TT, Saberi, FA (2015) Strategies for treatment of dystonia. J Neural Transm (epub ahead of printing).Google ScholarPubMed
Duane, DD, Monroe, J, Morris, RE (2000) Mycophenolate in the prevention of recurrent neutralizing botulinum toxin A antibodies in cervical dystonia. Mov Disord 15:365–366.3.0.CO;2-0>CrossRefGoogle ScholarPubMed
Frevert, J, Dressler, D (2010) Complexing proteins in botulinum toxin type A drugs: a help or a hindrance? Biologics 4:325–332.Google ScholarPubMed
Gonnering, RS (1988) Negative antibody response to long-term treatment of facial spasm with botulinum toxin. Am J Ophthalmol 105:313–315.CrossRefGoogle ScholarPubMed
Greene, PE, Fahn, S (1993) Use of botulinum toxin type F injections to treat torticollis in patients with immunity to botulinum toxin type A. Mov Disord 8:479–483.Google Scholar
Greene, P, Fahn, S, Diamond, B (1994) Development of resistance to botulinum toxin type A in patients with torticollis. Mov Disord 9:213–217.Google Scholar
Hanna, PA, Jankovic, J (1998) Mouse bioassay versus Western blot assay for botulinum toxin antibodies: correlation with clinical response. Neurology 50:1624–1629.CrossRefGoogle ScholarPubMed
Jankovic, J, Schwartz, K (1995) Response and immunoresistance to botulinum toxin injections. Neurology 45:1743–1746.Google Scholar
Kessler, KR, Benecke, R (1997) The EBD test: a clinical test for the detection of antibodies to botulinum toxin type A. Mov Disord 12:95–99.Google Scholar
Naumann, M, Toyka, KV, Mansouri Taleghani, B, Ahmadpour, J, Reiners, K, Bigalke, H (1998) Depletion of neutralising antibodies resensitises a secondary non-responder to botulinum A neurotoxin. J Neurol Neurosurg Psychiat 65:924–927.CrossRefGoogle ScholarPubMed
Rossetto, O, Pirazzini, M, Montecucco, C (2014) Botulinum neurotoxins: genetic, structural and mechanistic insights. Nat Rev Microbiol 12:535–549.CrossRefGoogle ScholarPubMed
Voller, B, Moraru, E, Auff, E, Benesch, M, Poewe, W, Wissel, J, Müller, J, Entner, T, Bigalke, H, Schnider, P (2004) Ninhydrin sweat test: a simple method for detecting antibodies neutralizing botulinum toxin type A. Mov Disord 19:943–947.CrossRefGoogle Scholar